Amarin Corp. PLC ADS (AMRN): Pfizer making money hand or fist but...

Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Followed By	33
Posts	4462
Boards Moderated	0
Alias Born	12/14/2013

Wednesday, December 08, 2021 11:01:59 AM

Re: KnowNothingJonSnow post# 362465

Pfizer making money hand or fist

but AMRN stock price is still way below $5 per share

since BPs like Pfizer focus their efforts on

what drugs make the most money (through hook or crook)

instead of what drugs are the best for society

Sometimes drugs that are best for society make lots of money

but, as in the case of AMRN and Vascepa,

apparently that is not so

Recent AMRN News

Proxy Statement (definitive) (def 14a) • Edgar (US Regulatory) • 05/24/2022 09:17:45 PM
HLS Therapeutics Obtains Public Reimbursement for Vascepa® in Quebec • PR Newswire (Canada) • 05/24/2022 11:28:00 AM
Current Report Filing (8-k) • Edgar (US Regulatory) • 05/20/2022 11:48:47 AM
Amarin Announces Appointment of New Directors and Board Leadership Changes • GlobeNewswire Inc. • 05/19/2022 12:23:13 PM
Research Presented at the American Heart Association’s Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA® (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated Costs • GlobeNewswire Inc. • 05/16/2022 12:00:00 PM
Amarin to Present at Two Upcoming Investor Conferences • GlobeNewswire Inc. • 05/12/2022 12:00:00 PM
Amarin Nosedives on Disappointing Quarterly Results • TipRanks • 05/05/2022 11:25:49 AM
Current Report Filing (8-k) • Edgar (US Regulatory) • 05/04/2022 11:10:45 AM
Quarterly Report (10-q) • Edgar (US Regulatory) • 05/04/2022 11:07:07 AM
Amarin Reports First Quarter 2022 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/04/2022 11:00:00 AM
New Analysis Reveals Icosapent Ethyl Significantly Reduces Risk of Major Cardiovascular Events in Patients with Prior Myocardial Infarction (Heart Attack) • GlobeNewswire Inc. • 05/03/2022 12:00:00 PM
Amended Annual Report (10-k/a) • Edgar (US Regulatory) • 05/02/2022 08:03:25 PM
Amarin Partner HLS Therapeutics Completes Reimbursement Negotiations with Pan-Canadian Pharmaceutical Alliance (pCPA) for VASCEPA® (icosapent ethyl) • GlobeNewswire Inc. • 04/26/2022 12:49:33 PM
Amarin to Report First Quarter 2022 Financial Results and Host Conference Call On May 4, 2022 • GlobeNewswire Inc. • 04/19/2022 11:30:00 AM
Analysts’ Top Healthcare Picks: Align Tech (ALGN), Amarin (AMRN) • TipRanks • 04/17/2022 12:36:06 PM
Eicosapentaenoic Acid (EPA) Combined with Widely Used Statins Significantly Reduced Lipid Oxidation in Model Membranes • GlobeNewswire Inc. • 04/01/2022 11:00:00 AM
AOUT, IMRX and AMRN among after hour movers • Seeking Alpha • 03/31/2022 10:13:47 PM
Amarin wins national reimbursement for Vazkepa in Sweden • Seeking Alpha • 03/28/2022 12:45:33 PM
Amarin Receives Reimbursement for VAZKEPA® in Sweden • GlobeNewswire Inc. • 03/28/2022 11:00:00 AM
Latest Research Evaluating VASCEPA® (Icosapent Ethyl) to be Presented at the American College of Cardiology’s 71st Annual Scientific Session • GlobeNewswire Inc. • 03/21/2022 12:30:00 PM
Amarin recovers amid positive views from Piper Sandler on European strategy • Seeking Alpha • 03/15/2022 07:23:25 PM
Amarin analysis shows Vascepa reduces risk of fatal cardiovascular events • Seeking Alpha • 03/10/2022 02:23:41 PM
Latest analysis shows VASCEPA® (icosapent ethyl) significantly lowered the risk of potentially fatal cardiovascular events in patients with prior percutaneous coronary intervention • GlobeNewswire Inc. • 03/10/2022 01:47:44 PM
Amarin stock rises after Q4 earnings beat amid Vascepa generic competition • Seeking Alpha • 03/01/2022 12:42:15 PM
Amarin Non-GAAP EPS of $0.06 beats by $0.09, revenue of $144.49M beats by $2.32M • Seeking Alpha • 03/01/2022 11:02:46 AM

More AMRN News

InvestorsHub NewsWire

FEATURED Emerging Markets Report: A Case for Uranium • May 26, 2022 10:07 AM

FEATURED Grove Inc. Upexi Division Launches Medicinal Mushroom Product Line Direct to Consumer and on Amazon • May 26, 2022 9:07 AM

FEATURED SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome • May 26, 2022 8:35 AM

Thunder Energies Signs $40 Million Funding Agreement • TNRG • May 26, 2022 4:30 PM

HNRC UPDATES ON SECOND $100 MILLION DOLLAR SPAC • HNRC • May 26, 2022 10:00 AM

Branded Legacy, Inc. Signs LOI To Acquire First Patent Thomas Pepper Johnson To Join Company's Executive Team • BLEG • May 26, 2022 8:30 AM

Dalrada Continues Upward Trajectory with 252% Growth in Third Quarter 2022 Financial Results • DFCO • May 26, 2022 8:00 AM

Atlanta Based Specialty Realty Group Reorganizes, Changes Business Plan & Leadership • TNRG • May 25, 2022 8:00 PM

OTC: ILUS, ILUS International (Ilustrato Pictures International Inc) Agrees Terms With an Acquisition Delivering Upwards of $100 Million in Annual Revenue • ILUS • May 25, 2022 11:52 AM

Branded Legacy, Inc. To Introduce New Delta 9 blend THC-0/Delta-8 Blend Gummies Sell Out Again • BLEG • May 25, 2022 8:30 AM

Goldshore Resources Announces Public (NSERC & MITACS) and Educational (Lakehead University) Tri-Party Institutional Partnership with Alliance Grant • GSHR • May 25, 2022 8:20 AM

Ultrack Systems Fully Acquires California Trucking Company M-Loan Inc. • MJLB • May 24, 2022 9:30 AM

SciSparc and Clearmind Medicine Inc. Collaboration Yields Positive Results for its Psychedelic Combination Treatment • CMND • May 24, 2022 8:36 AM

PSYC Teams Up with The Spore Group to Bring Industry-Leading, Psychedelic-Focused Events to Communities Across North America • PSYC • May 24, 2022 8:30 AM

Splash Beverage Group Broadens Reach through Agreement with Maryland's Buck Distributing • SBEV • May 24, 2022 8:12 AM

Start posting your company's news
Only $200 per official company press release!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
2M
3M
6M
1Y
2Y
3Y
5Y

Detailed Quote

Follow Board

Keyboard Shortcuts

Report TOS Violation